My Wall Street Journal @WSJopinion piece on Miami "Getting Richer-and Smaller" - @WSJ Miami isn't shrinking — it's evolving the way New York once did: a global core in Miami-Dade, with Broward and Palm Beach powering the region's growth. (I missed the paper version as we were in Chicago for @ASCO #ASCO26) @SylvesterCancer @univmiami @UMiamiHealth

Not to brag….. but look whose 🥇 on the morphology leaderboard 🙋🏻‍♀️ 😎 at the cancilico booth at @EHA_Hematology #EHA2026 Scan the QR and test yourself

Honored to receive the International Society of Oncology Prevention and Treatments (ISOPT) Precision Oncology Research Award in Hong Kong this evening. @BrownUniversity #LegorretaCancerCenter @WIN_Consortium

There’s still time to share your work and help shape the future of cancer care Submit your abstract to the @ASCO #ASCOQLTY26 and join a community dedicated to advancing person-centered, high-quality oncology care 🗓️ Deadline: June 16, 11:59 PM ET asco.confex.com/asco/qcs2026…

One of the big stories from #ASCO26 still making waves: GLP-1 drugs & #lungcancer, drawing headlines like this one. Really interesting, but early & easy to over-read. The finding is about slower progression in people already diagnosed with lung cancer who were also being treated for diabetes. It is not evidence these drugs prevent lung cancer, & it does not mean they treat it. The study was observational, so it cannot show cause. #LCSM lungcancereuropenews.eu/news…

🫁 In PD-L1-negative advanced NSCLC, the choice of first-line immunotherapy combination may matter. A multicenter retrospective cohort study published in Lung Cancer compared two widely used first-line regimens in advanced NSCLC without actionable driver mutations: ➡️ Nivolumab ipilimumab chemotherapy ➡️ Pembrolizumab chemotherapy The analysis included 457 patients treated across 13 institutions in Japan. Patients were stratified by PD-L1 tumor proportion score: 📌 PD-L1 TPS <1% 📌 PD-L1 TPS ≥1% The strongest signal came from the PD-L1-Negative Advanced NSCLC cohort. With follow-up exceeding 40 months, nivolumab plus ipilimumab with chemotherapy showed longer overall survival than pembrolizumab with chemotherapy: 📌 Median OS: 47.4 vs 16.6 months 📌 Adjusted HR: 0.50 📌 36-month OS rate: 51.5% vs 28.2% In patients with PD-L1 TPS ≥1%, survival outcomes were similar between the two regimens. Safety was broadly comparable, although severe skin toxicity and adrenal-pituitary disorders were more frequent with nivolumab plus ipilimumab. The takeaway: For PD-L1-Negative Advanced NSCLC, dual checkpoint blockade plus chemotherapy may provide a sustained long-term survival advantage — but prospective validation is still needed. Reference: Kinehara et al., Lung Cancer, 2026. #OncoDailyLung #NSCLC

🚨Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation | Journal of Clinical Oncology @JCO_ASCO @ASCO @JiaJennyLiu @JulianaRBeal @niamhjcoleman @OncoAlert ascopubs.org/doi/10.1200/JCO…

What has changed most in pulmonary medicine over the last two decades? An international group of pulmonologists shares their perspective on the evolving role of the specialty in lung cancer care as part of JTO’s 20th Anniversary series. Read now: bit.ly/4e0oBQk

In this study, Zanghì et al. used peripheral blood mononuclear cell profiling to personalize LDCT screening intervals to combat false positives and increase accuracy. 📑Read more: bit.ly/3OrV5tR @IstTumori

Have you registered yet? See you in @seoul for @iaslc #WCLC26

📰 Breaking: ILCN editorial board member Dr. @ShirishGadgeel has been appointed to the thoracic oncology team at Winship Cancer Institute. Read more details in ILCN: bit.ly/4uFT8tU

Honoured to publish an editorial in JCO GO accompanying a randomized trial on CRC survivorship in North Africa. Key message: Exercise is not adjunct—it is treatment. scalable interventions like physical activity may be among the most powerful tools to improve outcomes.

Technically MTAP loss and the resulting therapeutic vulnerability created is an example of “collateral lethality”. statnews.com/2026/06/11/synt… A term first proposed by @RonDePinho nature.com/articles/nature21… However there may be an element of synthetic lethality here as well…(1/2)

Our new position statement outlines ways to expand eligibility, increase funding & expand community access for pediatric oncology clinical trials. Learn more: bit.ly/4v1q7J7 #ASCOAdvocacy

Thank you! Already a lot of fun! And we are only just starting! Great work and energy from our GI group! @MPishvaian @GIMedOnc @YJanjigianMD @mgfakih @GlopesMd Great to see the algorithm on Daraxonrasib! @EileenMOReilly myopenmedicine.com/algorithm…

📆 Early Bird registration for #WCLC26 ends tomorrow! Register by June 12 to save up to $500. IASLC Members can save up to $750 total. Register now: bit.ly/wclcreg26

Turning Advanced Lung Cancer Into a Chronic Disease - CUHK Medicine @CUHKMedicine

We're learning a lot about cellular senescence, how to track it, and its role in aging and disease. Cover and commentary @CellCellPress cell.com/cell/fulltext/S0092…

Incredibly proud of this class of rising oncologists from UMMSM/JMH 👏 Truly a pleasure and joy getting to know and work alongside them Wishing you all endless success

What if patients helped design the research that impacts them? Meet our Citizen Scientists!! Over the next 6 months, they’ll gain the tools to turn lived experience into real research impact. From crafting research questions to understanding how studies are built. This is more than training. It’s about giving our community a voice in shaping the future of lung cancer research. Learn more our newest cohort of Citizen Scientists and about program by visiting citizenscientistprogram.org/

📣 Tell Congress to support the #SeniorsAct with already 290 bipartisan sponsors to #FixPriorAuthorization #ASCOAdvocacy 👇👇